Core Points - The implementation details of the cumulative voting system aim to enhance the corporate governance structure of Anhui Huaren Health Pharmaceutical Co., Ltd. and protect the interests of minority shareholders [3] - The cumulative voting system allows shareholders to allocate their voting rights across multiple candidates when electing two or more directors, providing flexibility in voting [3][5] - The election process for directors must comply with the company's articles of association and relevant laws, ensuring a structured and transparent nomination and voting process [3][4] Section Summaries General Provisions - The cumulative voting system is established to improve corporate governance and protect minority shareholders' interests, in accordance with relevant laws and regulations [3] - The system allows shareholders to have voting rights equal to the number of shares they hold multiplied by the number of directors to be elected [3] Election and Voting of Directors - The board must inform shareholders about the cumulative voting method before the election, and appropriate ballots must be prepared [2][3] - The election of independent and non-independent directors is conducted separately, with specific voting rights allocated for each category [5] - Shareholders can concentrate or distribute their votes among candidates, but exceeding the allowed number of votes will render the ballot invalid [5] Nomination of Director Candidates - Candidates for the board must be nominated by shareholders holding at least 1% of the company's shares or by the board itself [3] - Nominators must obtain consent from candidates and ensure they meet the qualifications for directorship [3][4] Election Results and Procedures - The number of elected directors must meet the requirements set forth in the company's articles of association, with a majority of votes needed for election [4] - If the number of elected directors is insufficient, additional rounds of voting will be conducted until the required number is met [4]

Core Viewpoint - The document outlines the procedures and requirements for selecting and changing accounting firms for Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the importance of maintaining independence and quality in the auditing process [1][2][3]. Group 1: General Principles - The audit fees for the accounting firm are determined by the shareholders' meeting [1] - The controlling shareholders and actual controllers are prohibited from designating accounting firms or interfering with the audit committee's independent duties [1] - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] Group 2: Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet the requirements set by the China Securities Regulatory Commission [1][2] - Firms must have a fixed workplace, sound organizational structure, and robust internal management systems [1] - The auditing team must include registered accountants who have not faced criminal or administrative penalties related to their professional conduct in the last three years [1][2] Group 3: Selection Procedures - The audit committee, independent directors, or a majority of the board can propose the hiring of an accounting firm [2][3] - The selection process must be competitive, utilizing methods such as competitive negotiation, public bidding, or invitation to tender [2][3] - The company must publicly disclose the selection documents, including evaluation criteria and scoring standards [2][3] Group 4: Evaluation and Reporting - The audit committee is responsible for evaluating the performance of the accounting firm annually and reporting to the board [2][3] - Evaluation criteria must include audit fees, qualifications, quality management, and risk management capabilities [4][5] - Significant changes in audit fees (over 20%) must be disclosed, including reasons for the change [6] Group 5: Change of Accounting Firms - The company must change accounting firms under specific circumstances, such as quality issues or failure to meet obligations [8][9] - The audit committee must communicate with both the outgoing and incoming firms to assess quality and integrity [9][10] - The reasons for changing firms must be disclosed, along with communication details with the previous firm [11][12]

Core Viewpoint - The core purpose of market value management is to align the company's market value with its intrinsic value by focusing on core business, enhancing operational efficiency, and improving core competitiveness [1][3]. Group 1: Objectives and Principles of Market Value Management - The primary objective of market value management is to enhance the company's value creation capability through effective information disclosure and investor relations management [1]. - The basic principles of market value management include compliance, systematic approach, scientific methods, normalization, and proactivity [4][2]. Group 2: Organizational Structure and Responsibilities - The board of directors leads the market value management efforts, with the chairman as the primary responsible person and the board secretary overseeing specific tasks [6]. - The board is responsible for establishing an internal control system for market value management, focusing on improving company quality and considering investor interests in major decisions [6]. Group 3: Main Methods of Market Value Management - Key methods for promoting the company's investment value include mergers and acquisitions, equity incentives, cash dividends, investor relations management, information disclosure, and share buybacks [7][6]. - The company should focus on its core business and improve operational efficiency while utilizing various methods to reflect the company's quality in its investment value [7][6]. Group 4: Monitoring and Early Warning Mechanism - The securities department is responsible for monitoring market value indicators and setting reasonable warning thresholds to analyze and report any significant changes [7]. - In the event of a significant or continuous decline in stock price, the company should take timely measures to analyze the reasons, communicate with investors, and potentially implement share buybacks or cash dividends [7].

Core Points - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., was established to protect the rights and interests of shareholders, employees, and creditors, and to regulate its organization and behavior according to relevant laws [3][4] - The company was registered with a capital of RMB 400.01 million and is a permanent corporation [4][5] - The company issued 60.01 million shares to the public and was listed on the Shenzhen Stock Exchange on March 1, 2023 [3][4] Chapter Summaries General Provisions - The company is established in accordance with the Company Law and other relevant regulations [3] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [4][5] - The company operates under the principle of "quality first, integrity-based" [4][5] Business Objectives and Scope - The registered name of the company is Anhui Huaren Health Pharmaceutical Co., Ltd., with its address in Hefei City [4] - The business scope includes drug wholesale, food sales, medical device sales, and various consulting services [4][5] Shares - The company has issued a total of 40.01 million shares, all of which are ordinary shares [6] - The company can provide financial assistance for others to acquire its shares, with a limit of 10% of the total issued capital [6][7] Shareholder and Shareholder Meeting - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][19] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [26][27] - Shareholders holding more than 10% of shares can request a temporary meeting [29][30] Voting and Resolutions - Resolutions can be ordinary or special, requiring a majority or two-thirds majority of the voting rights, respectively [79] - The company must ensure that the meeting records are accurate and preserved for at least ten years [41]

安徽华人健康医药股份有限公司 内幕信息知情人登记管理制度 第一章 总则 董事会秘书具体负责公司内幕信息的日常管理工作，证券部是公司信息 披露管理、投资者关系管理、内幕信息登记备案的日常办事机构。 公司审计委员会对内幕信息知情人登记管理制度实施情况进行监督。 第二章 内幕信息及内幕信息知情人的范围 第六条 本制度所指内幕信息是指根据《证券法》相关规定，涉及公司的经营、 财务或者对公司股票、证券及其衍生品种交易价格有重大影响的尚未公 开的信息。包括但不限于： （一）公司的经营方针和经营范围的重大变化； （二）公司的重大投资行为，公司在一年内购买、出售重大资产超过公 司资产总额百分之三十，或者公司营业用主要资产的抵押、质押、出售 或者报废一次超过该资产的百分之三十； （三）公司订立重要合同、提供重大担保或者从事关联交易，可能对公 司的资产、负债、权益和经营成果产生重要影响； （四）公司发生重大债务和未能清偿到期债务的违约情况； （五）公司发生重大亏损或者重大损失； （六）公司生产经营的外部条件发生的重大变化； （七）公司的董事、或者总裁发生变动，董事长或者总裁无法履行职责； （八）持有公司百分之五以上股份的股东或者 ...

Core Viewpoint - The pharmaceutical and biotechnology industry is experiencing moderate performance, with the introduction of the commercial insurance innovative drug catalog and the deepening application of artificial intelligence in healthcare presenting structural opportunities for growth [1][3]. Group 1: Commercial Insurance Innovative Drug Catalog - The National Healthcare Security Administration and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, establishing a commercial insurance innovative drug catalog that focuses on innovative drugs with significant clinical value but outside the scope of medical insurance [1]. - The catalog aims to eliminate barriers for high-value innovative drugs through a "three exclusions" policy, which does not count towards the self-pay rate of medical insurance, monitors alternative products, and limits payment by disease type [1]. - The actual effectiveness of the catalog depends on the payment capabilities of commercial insurance and the collaboration with medical institutions, with the current payment proportion for innovative drugs being less than 8%, while the policy aims to increase this to 44% over the next decade [1][2]. Group 2: AI in Healthcare - Artificial intelligence is rapidly penetrating the entire pharmaceutical industry chain, significantly shortening drug development cycles and reducing costs through target screening, molecular design, and clinical trial optimization [3]. - The National Science and Technology Major Project has allocated 1.75 billion yuan for AI-assisted new drug development projects, focusing on breakthroughs in infectious diseases and rare diseases by 2025 [3]. - The intelligent transformation of medical services is also accelerating, with AI-assisted diagnostic systems becoming more mature in applications such as imaging recognition and pathological analysis [3]. - Despite optimism about the long-term potential of AI technology, challenges such as data fragmentation, privacy protection, and the lack of interpretability of AI models remain significant barriers to large-scale application [3].

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Group 1 - The company has announced its 2024 annual profit distribution plan, which involves a cash dividend of 3.5 RMB per 10 shares for all shareholders, based on a total share capital of 388,516,736 shares [1][2] - The distribution plan is consistent with the allocation scheme approved by the shareholders' meeting and will be adjusted if the total share capital changes before the implementation [1] - The record date for the distribution is set for July 9, 2025, and the ex-dividend date is July 10, 2025 [1][2] Group 2 - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date [2] - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [2] - The company assumes all legal responsibilities for any insufficient cash dividends due to a decrease in shares held by shareholders during the distribution application period [2]

Core Viewpoint - The company has approved the use of up to RMB 2.5 billion of idle self-owned funds for cash management, which includes investments in various financial products to enhance investment efficiency and returns for shareholders [1][2]. Cash Management Overview - The company will utilize idle funds for cash management, including fixed-income or capital-protected floating income financial products, large deposits, and time deposits [1]. - A contract has been signed with Guangfa Bank for a structured deposit linked to gold, with expected annual returns of 1%, 2%, or 2.1% [1][4]. Investment Risk Analysis - The cash management investments are considered low-risk, but they may still be affected by macroeconomic conditions and market fluctuations [2]. - The company will monitor the financial market and adjust its investment strategy accordingly to mitigate risks [2]. Impact on Company - The cash management strategy aims to improve the overall performance of the company and provide better returns to shareholders without affecting the normal operations of the company or its main business activities [2].

Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]